Temaz and Coronary arterial stent insertion - a phase IV clinical study of FDA data

Summary:

Coronary arterial stent insertion is reported as a side effect among people who take Temaz (temazepam), especially for people who are male, 60+ old, also take Plavix, and have Arthritis.

The phase IV clinical study analyzes which people have Coronary arterial stent insertion when taking Temaz. It is created by eHealthMe based on reports of 40,916 people who have side effects when taking Temaz from the FDA, and is updated regularly.

What is Temaz?

Temaz has active ingredients of temazepam. It is often used in insomnia. eHealthMe is studying from 42,293 Temaz users. Check the latest studies of Temaz.

What is Coronary arterial stent insertion?

Coronary arterial stent insertion is found to be associated with 370 drugs and 490 conditions by eHealthMe. Check the latest studies of Coronary arterial stent insertion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

40,916 people reported to have side effects when taking Temaz.
Among them, 15 people (0.04%) have Coronary arterial stent insertion.

Could Temaz cause Coronary arterial stent insertion?

Among these 15 people:

What is the gender of people who have Coronary arterial stent insertion when taking Temaz? *

female: 20 %
male: 80 %

What is the age of people who have Coronary arterial stent insertion when taking Temaz? *

What are other drugs people take besides Temaz? *

Amoxicillin: 9 people, 60.00%
Aspirin: 9 people, 60.00%
Plavix: 9 people, 60.00%
Sertraline Hydrochloride: 8 people, 53.33%
Zocor: 8 people, 53.33%
Nitroglycerin: 8 people, 53.33%
Simvastatin: 8 people, 53.33%
Zoloft: 8 people, 53.33%
Lovaza: 7 people, 46.67%
Senna: 7 people, 46.67%

What are other side effects people have besides Coronary arterial stent insertion? *

Injury: 9 people, 60.00%
Infection: 8 people, 53.33%
Fainting (loss of consciousness and postural tone): 8 people, 53.33%
Stress And Anxiety: 8 people, 53.33%
Oral Pain: 7 people, 46.67%
Bone Density Decreased: 7 people, 46.67%
Mastication Disorder (disease of chewing food): 7 people, 46.67%
Oral Disorder (mouth disease): 7 people, 46.67%
Fall: 7 people, 46.67%
Bone Pain: 7 people, 46.67%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 7 people, 46.67%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 7 people, 46.67%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 13.33%
Prostate Cancer: 1 person, 6.67%
High Density Lipoprotein Decreased: 1 person, 6.67%
High Blood Cholesterol: 1 person, 6.67%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Temaz and have Coronary arterial stent insertion?

- Check whether Coronary arterial stent insertion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Temaz:

Temaz (42,293 reports)

Browse all side effects of Temaz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Coronary arterial stent insertion:

Coronary arterial stent insertion (370 drugs)

Browse all the conditions that are associated with Coronary arterial stent insertion:

Coronary arterial stent insertion (490 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on temazepam (the active ingredients of Temaz) and Temaz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.